Related references
Note: Only part of the references are listed.Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Sil Kordes et al.
LANCET ONCOLOGY (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation
Nicole F. Neel et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma
Robert J. Torphy et al.
PLOS ONE (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells
Enza Lonardo et al.
PLOS ONE (2013)
Metformin improves healthspan and lifespan in mice
Alejandro Martin-Montalvo et al.
NATURE COMMUNICATIONS (2013)
AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets
Ken Inoki et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells
Bin Bao et al.
CANCER PREVENTION RESEARCH (2012)
Metformin and Pancreatic Cancer: A Clue Requiring Investigation
Michael Pollak
CLINICAL CANCER RESEARCH (2012)
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Navid Sadeghi et al.
CLINICAL CANCER RESEARCH (2012)
Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells
Weiguang Li et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2012)
Targeting AMPK in the treatment of malignancies
Eliza Vakana et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
AMPK: a nutrient and energy sensor that maintains energy homeostasis
D. Grahame Hardie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Davide Soranna et al.
ONCOLOGIST (2012)
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
Michael N. Pollak
CANCER DISCOVERY (2012)
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
Isaam Ben Sahra et al.
CANCER RESEARCH (2011)
Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner
R. Rattan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth
Yin-Hsun Feng et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
AMP-activated protein kinase: nature's energy sensor
David Carling et al.
NATURE CHEMICAL BIOLOGY (2011)
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
Marc Foretz et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth
R. J. Shaw
ACTA PHYSIOLOGICA (2009)
Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth
Krisztina Kisfalvi et al.
CANCER RESEARCH (2009)
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
Alejandro Vazquez-Martin et al.
CELL CYCLE (2009)
Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients
B. Rubio-Viqueira et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
New Users of Metformin Are at Low Risk of Incident Cancer A cohort study among people with type 2 diabetes
Gillian Libby et al.
DIABETES CARE (2009)
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
Walter H. Gotlieb et al.
GYNECOLOGIC ONCOLOGY (2008)
AMPK and raptor: Matching cell growth to energy supply
D. Grahame Hardie
MOLECULAR CELL (2008)
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Dana M. Gwinn et al.
MOLECULAR CELL (2008)
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
I. Ben Sahra et al.
ONCOGENE (2008)
Metformin induces apoptosis of pancreatic cancer cells
Luo-Wei Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP
Yong Deuk Kim et al.
DIABETES (2008)
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells
Ryan J. O. Dowling et al.
CANCER RESEARCH (2007)
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Mahvash Zakikhani et al.
CANCER RESEARCH (2006)
mTOR and cancer: insights into a complex relationship
David M. Sabatini
NATURE REVIEWS CANCER (2006)
An in vivo platform for translational drug development in pancreatic cancer
Belen Rubio-Viqueira et al.
CLINICAL CANCER RESEARCH (2006)
Metformin and reduced risk of cancer in diabetic patients
JMM Evans et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.
DR Bolster et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
